clinical trial · NCT07393659
A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment
ViiV Healthcare·phase3·not yet recruiting·n = 183
HIV InfectionsFostemsavirDolutegravir (DTG)/ Lamivudine (3TC)
brief summary
The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent study. This continued access will also allow further collection of safety data. Eligible participants are those who completed a ViiV Healthcare-sponsored or collaborative parent study and are currently experiencing clinical benefit. The Sponsor will periodically review the study to consider other treatment access options.
started
May 8, 2026
primary completion
Dec 30, 2030
completion
Dec 30, 2030
last updated
Feb 6, 2026
official title
A Phase 3b, Open-label, Multicenter, Continued Access Study for Participants Transitioning From ViiV Healthcare Sponsored or ViiV Healthcare Collaborative Parent Studies for HIV Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol